{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:33:54Z","timestamp":1782761634614,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072807"],"award-info":[{"award-number":["82072807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bladder cancer (BLCA) ranks among the most prevalent malignancies of the urinary system, with its clinical diagnosis predominantly reliant on invasive procedures. Traditional chemotherapy regimens exhibit significant limitations, underscoring the urgency of identifying novel diagnostic biomarkers and strategies to enhance chemotherapy efficacy. CDCA3 has been recognized as a facilitator of BLCA progression, activated by MYBL2. However, its precise regulatory mechanisms in BLCA pathogenesis remain incompletely elucidated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>To investigate the functional role of CDCA3 in BLCA, MTT and colony formation assays were employed to assess cellular proliferation, while flow cytometry was utilized to evaluate apoptosis and intracellular ROS levels. The expression of CDCA3, ENO1, TRIM28, and MYC was analyzed through WB and qRT-PCR, and Co-IP assays were conducted to delineate interactions among CDCA3, TRIM28, and MYC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>CDCA3, a key regulator of the cell cycle, facilitates BLCA glycolysis by modulating the transcriptional expression of \u03b1-Enolase (ENO1), thereby enhancing BLCA progression. Mechanistically, CDCA3 recruits TRIM28, which stabilizes MYC, while MYC transcriptionally upregulates <jats:italic>CDCA3<\/jats:italic>, establishing a self-reinforcing CDCA3-MYC feedback loop. A risk prediction model incorporating the expression profiles of <jats:italic>CDCA3<\/jats:italic> and <jats:italic>ENO1<\/jats:italic> was developed to evaluate the overall survival of patients with BLCA. This model provides a prognostic tool to predict survival outcomes in patients with BLCA based on <jats:italic>CDCA3<\/jats:italic> and <jats:italic>ENO1<\/jats:italic> expression levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study delineates a novel role for CDCA3 in the regulation of BLCA glycolysis and identifies its interaction with MYC as a critical positive feedback mechanism, providing fresh insights into the molecular mechanisms underlying BLCA progression.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03325-7","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T09:19:12Z","timestamp":1740043152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis"],"prefix":"10.1186","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6990-3440","authenticated-orcid":false,"given":"Dexin","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongpan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"3325_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Giaquinto AN, Jemal A, Cancer statistics. CA Cancer J Clin 2024. 2024;74(1):12\u201349.","DOI":"10.3322\/caac.21820"},{"issue":"5","key":"3325_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404\u201323.","journal-title":"CA Cancer J Clin"},{"issue":"23","key":"3325_CR3","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1158\/1078-0432.CCR-23-3518","volume":"30","author":"A Flechon","year":"2024","unstructured":"Flechon A, Morales-Barrera R, Powles T, Alva A, Ozguroglu M, Csoszi T, et al. Association of Tumor Mutational Burden and PD-L1 with the efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma. Clin Cancer Res. 2024;30(23):5353\u201364.","journal-title":"Clin Cancer Res"},{"key":"3325_CR4","doi-asserted-by":"crossref","unstructured":"Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, et al. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med; 2024.","DOI":"10.1038\/s41591-024-03324-9"},{"key":"3325_CR5","doi-asserted-by":"crossref","unstructured":"Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, et al. FGFR inhibition in Urothelial Carcinoma. Eur Urol; 2024.","DOI":"10.1016\/j.eururo.2024.09.012"},{"issue":"12","key":"3325_CR6","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, et al. Efficacy and safety of Disitamab Vedotin in patients with human epidermal growth factor receptor 2-Positive locally Advanced or Metastatic Urothelial Carcinoma: a combined analysis of two phase II clinical trials. J Clin Oncol. 2024;42(12):1391\u2013402.","journal-title":"J Clin Oncol"},{"key":"3325_CR7","doi-asserted-by":"crossref","unstructured":"Hanahan D, Hallmarks of Cancer. New Dimensions Cancer Discov. 2022;12(1):31\u201346.","DOI":"10.1158\/2159-8290.CD-21-1059"},{"issue":"1","key":"3325_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.yexcr.2015.04.007","volume":"335","author":"VR Conde","year":"2015","unstructured":"Conde VR, Oliveira PF, Nunes AR, Rocha CS, Ramalhosa E, Pereira JA, Alves MG. Silva BM the progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism. Exp Cell Res. 2015;335(1):91\u20138.","journal-title":"Exp Cell Res"},{"issue":"19","key":"3325_CR9","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1002\/elps.201300228","volume":"34","author":"K Dettmer","year":"2013","unstructured":"Dettmer K, Vogl FC, Ritter AP, Zhu W, Nurnberger N, Kreutz M, Oefner PJ, Gronwald W. Gottfried E distinct metabolic differences between various human cancer and primary cells. Electrophoresis. 2013;34(19):2836\u201347.","journal-title":"Electrophoresis"},{"issue":"9","key":"3325_CR10","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1111\/cas.15047","volume":"112","author":"JE Burns","year":"2021","unstructured":"Burns JE, Hurst CD, Knowles MA, Phillips RM, Allison SJ. The Warburg effect as a therapeutic target for bladder cancers and intratumoral heterogeneity in associated molecular targets. Cancer Sci. 2021;112(9):3822\u201334.","journal-title":"Cancer Sci"},{"key":"3325_CR11","doi-asserted-by":"publisher","first-page":"101059","DOI":"10.1016\/j.drup.2024.101059","volume":"73","author":"F Li","year":"2024","unstructured":"Li F, Zhang H, Huang Y, Li D, Zheng Z, Xie K, et al. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat. 2024;73:101059.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"3325_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12943-023-01856-1","volume":"22","author":"B Xie","year":"2023","unstructured":"Xie B, Lin J, Chen X, Zhou X, Zhang Y, Fan M, et al. CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer. Mol Cancer. 2023;22(1):151.","journal-title":"Mol Cancer"},{"issue":"2","key":"3325_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"LE Raez","year":"2013","unstructured":"Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71(2):523\u201330.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3325_CR14","doi-asserted-by":"crossref","unstructured":"Zou RC, Guo ZT, Wei D, Shi ZT, Ye ZC, Zhai G et al. Downregulation of CDCA3 expression inhibits tumor formation in pancreatic cancer. Neoplasma. 2020;67(6):1223\u201332.","DOI":"10.4149\/neo_2020_200411N388"},{"issue":"5","key":"3325_CR15","first-page":"2021","volume":"53","author":"W Qian","year":"2018","unstructured":"Qian W, Zhang Z, Peng W, Li J, Gu Q, Ji D, et al. CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer. Int J Oncol. 2018;53(5):2021\u201333.","journal-title":"Int J Oncol"},{"issue":"7","key":"3325_CR16","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jtho.2017.04.018","volume":"12","author":"MN Adams","year":"2017","unstructured":"Adams MN, Burgess JT, He Y, Gately K, Snell C, Zhang SD, Hooper JD, Richard DJ. O\u2019Byrne KJ expression of CDCA3 is a prognostic biomarker and potential therapeutic target in Non-small Cell Lung Cancer. J Thorac Oncol. 2017;12(7):1071\u201384.","journal-title":"J Thorac Oncol"},{"key":"3325_CR17","doi-asserted-by":"crossref","unstructured":"Gu P, Zhang M, Zhu J, He X, Yang D. Suppression of CDCA3 inhibits prostate cancer progression via NF\u2013kappaB\/cyclin D1 signaling inactivation and p21 accumulation. Oncol Rep 2022;47(2).","DOI":"10.3892\/or.2021.8253"},{"issue":"19","key":"3325_CR18","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood.2020005569","volume":"136","author":"J Chen","year":"2020","unstructured":"Chen J, Goyal N, Dai L, Lin Z, Del Valle L, Zabaleta J, et al. Developing new ceramide analogs and identifying novel sphingolipid-controlled genes against a virus-associated lymphoma. Blood. 2020;136(19):2175\u201387.","journal-title":"Blood"},{"issue":"7","key":"3325_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41419-020-2713-8","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu Y, Cheng G, Huang Z, Bao L, Liu J, Wang C, et al. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma. Cell Death Dis. 2020;11(7):515.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3325_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12935-021-01969-x","volume":"21","author":"D Shen","year":"2021","unstructured":"Shen D, Fang Y, Zhou F, Deng Z, Qian K, Wang G, Xiao Y, Ju L, Wang X. The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma. Cancer Cell Int. 2021;21(1):257.","journal-title":"Cancer Cell Int"},{"issue":"41","key":"3325_CR21","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1038\/s41388-022-02456-x","volume":"41","author":"W Liu","year":"2022","unstructured":"Liu W, Shen D, Ju L, Zhang R, Du W, Jin W, et al. MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3. Oncogene. 2022;41(41):4606\u201317.","journal-title":"Oncogene"},{"key":"3325_CR22","doi-asserted-by":"crossref","unstructured":"Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nat. 2017;546(7658):426\u201330.","DOI":"10.1038\/nature22797"},{"issue":"1","key":"3325_CR23","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1038\/s41467-022-32163-w","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Ding K, Li X, Yuan B, Wang Y, Yao Z, et al. Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH). Nat Commun. 2022;13(1):4549.","journal-title":"Nat Commun"},{"issue":"1","key":"3325_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13000-020-01048-1","volume":"15","author":"K Zhang","year":"2020","unstructured":"Zhang K, Hu H, Xu J, Qiu L, Chen H, Jiang X. Jiang Y Circ_0001421 facilitates glycolysis and lung cancer development by regulating miR-4677-3p\/CDCA3. Diagn Pathol. 2020;15(1):133.","journal-title":"Diagn Pathol"},{"issue":"7","key":"3325_CR25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41388-023-02922-0","volume":"43","author":"J Yu","year":"2024","unstructured":"Yu J, Li M, Ju L, Zhou F, Wang Y, Zhang Y, et al. TRAIP suppresses bladder cancer progression by catalyzing K48-linked polyubiquitination of MYC. Oncogene. 2024;43(7):470\u201383.","journal-title":"Oncogene"},{"issue":"4","key":"3325_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41419-023-05770-8","volume":"14","author":"D Shen","year":"2023","unstructured":"Shen D, Deng Z, Liu W, Zhou F, Fang Y, Shan D, et al. Melatonin inhibits bladder tumorigenesis by suppressing PPARgamma\/ENO1-mediated glycolysis. Cell Death Dis. 2023;14(4):246.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3325_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13046-021-02229-6","volume":"41","author":"S Dong","year":"2022","unstructured":"Dong S, Liang S, Cheng Z, Zhang X, Luo L, Li L, et al. ROS\/PI3K\/Akt and Wnt\/beta-catenin signalings activate HIF-1alpha-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. J Exp Clin Cancer Res. 2022;41(1):15.","journal-title":"J Exp Clin Cancer Res"},{"key":"3325_CR28","doi-asserted-by":"publisher","first-page":"1013035","DOI":"10.3389\/fonc.2022.1013035","volume":"12","author":"J Gu","year":"2022","unstructured":"Gu J, Zhong K, Wang L, Ni H, Zhao Y, Wang X, et al. ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway. Front Oncol. 2022;12:1013035.","journal-title":"Front Oncol"},{"issue":"10","key":"3325_CR29","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.7150\/ijbs.69332","volume":"18","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Xu P, Hu Z, Fu Z, Deng T, Deng X, et al. CCDC65, a Gene Knockout that leads to early death of mice, acts as a potentially novel tumor suppressor in Lung Adenocarcinoma. Int J Biol Sci. 2022;18(10):4171\u201386.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"3325_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41467-021-27609-6","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, Chen C, Song Z, Wang H, Ye M, Wang D, Kang W, Liu H, Qing G. EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation. Nat Commun. 2022;13(1):12.","journal-title":"Nat Commun"},{"issue":"1","key":"3325_CR31","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1038\/s41467-018-07475-5","volume":"9","author":"KW Fong","year":"2018","unstructured":"Fong KW, Zhao JC, Song B, Zheng B, Yu J. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression. Nat Commun. 2018;9(1):5007.","journal-title":"Nat Commun"},{"issue":"1","key":"3325_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41392-023-01450-3","volume":"8","author":"X Ma","year":"2023","unstructured":"Ma X, Jia S, Wang G, Liang M, Guo T, Du H, et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal Transduct Target Ther. 2023;8(1):246.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3325_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13046-024-03040-9","volume":"43","author":"Y Yang","year":"2024","unstructured":"Yang Y, Zhang Y, Chen G, Sun B, Luo F, Gao Y, Feng H, Li Y. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m(6)a reader YTHDC1 protein degradation. J Exp Clin Cancer Res. 2024;43(1):141.","journal-title":"J Exp Clin Cancer Res"},{"key":"3325_CR34","doi-asserted-by":"crossref","unstructured":"Agarwal N, Rinaldetti S, Cheikh BB, Zhou Q, Hass EP, Jones RT et al. TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer. Proc Natl Acad Sci U S A 2021, 118(38).","DOI":"10.1073\/pnas.2102423118"},{"issue":"1","key":"3325_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41597-020-0458-y","volume":"7","author":"K Upton","year":"2020","unstructured":"Upton K, Modi A, Patel K, Kendsersky NM, Conkrite KL, Sussman RT, et al. Epigenomic profiling of neuroblastoma cell lines. Sci Data. 2020;7(1):116.","journal-title":"Sci Data"},{"issue":"37","key":"3325_CR36","doi-asserted-by":"publisher","first-page":"E7697","DOI":"10.1073\/pnas.1710366114","volume":"114","author":"K Satoh","year":"2017","unstructured":"Satoh K, Yachida S, Sugimoto M, Oshima M, Nakagawa T, Akamoto S, et al. Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proc Natl Acad Sci U S A. 2017;114(37):E7697\u2013706.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3325_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41422-020-0372-z","volume":"31","author":"J Liu","year":"2021","unstructured":"Liu J, Peng Y, Shi L, Wan L, Inuzuka H, Long J, et al. Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Res. 2021;31(1):80\u201393.","journal-title":"Cell Res"},{"issue":"4","key":"3325_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","volume":"16","author":"CV Dang","year":"2006","unstructured":"Dang CV, O\u2019Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253\u201364.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"3325_CR39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13046-022-02412-3","volume":"41","author":"Z Jing","year":"2022","unstructured":"Jing Z, Liu Q, He X, Jia Z, Xu Z, Yang B, Liu P. NCAPD3 enhances Warburg effect through c-myc and E2F1 and promotes the occurrence and progression of colorectal cancer. J Exp Clin Cancer Res. 2022;41(1):198.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"3325_CR40","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1158\/1078-0432.CCR-05-0534","volume":"11","author":"P Bachireddy","year":"2005","unstructured":"Bachireddy P, Bendapudi PK. Felsher DW getting at MYC through RAS. Clin Cancer Res. 2005;11(12):4278\u201381.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3325_CR41","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4161\/cc.3.9.1145","volume":"3","author":"RC Sears","year":"2004","unstructured":"Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle. 2004;3(9):1133\u20137.","journal-title":"Cell Cycle"},{"issue":"1","key":"3325_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41419-024-06446-7","volume":"15","author":"M Li","year":"2024","unstructured":"Li M, Yu J, Ju L, Wang Y, Jin W, Zhang R, et al. USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer. Cell Death Dis. 2024;15(1):44.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3325_CR43","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1038\/s41467-023-38160-x","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Ju L, Wang G, Qian K, Jin W, Li M, et al. DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC. Nat Commun. 2023;14(1):2421.","journal-title":"Nat Commun"},{"issue":"1","key":"3325_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0092-8674(03)00232-0","volume":"113","author":"NG Ayad","year":"2003","unstructured":"Ayad NG, Rankin S, Murakami M, Jebanathirajah J, Gygi S, Kirschner MW. Tome-1, a trigger of mitotic entry, is degraded during G1 via the APC. Cell. 2003;113(1):101\u201313.","journal-title":"Cell"},{"issue":"5","key":"3325_CR45","doi-asserted-by":"publisher","first-page":"189147","DOI":"10.1016\/j.bbcan.2024.189147","volume":"1879","author":"Z Wang","year":"2024","unstructured":"Wang Z, Ren M, Liu W, Wu J, Tang P. Role of cell division cycle-associated proteins in regulating cell cycle and promoting tumor progression. Biochim Biophys Acta Rev Cancer. 2024;1879(5):189147.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7278","key":"3325_CR46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature08674","volume":"463","author":"HM Rowe","year":"2010","unstructured":"Rowe HM, Jakobsson J, Mesnard D, Rougemont J, Reynard S, Aktas T, et al. KAP1 controls endogenous retroviruses in embryonic stem cells. Nature. 2010;463(7278):237\u201340.","journal-title":"Nature"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03325-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03325-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03325-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T09:19:19Z","timestamp":1740043159000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03325-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3325"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03325-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics committee of experimental animals of The First Affiliated Hospital of University of Science and Technology of China granted ethical approval for this study (approval number: 202404122018000509629).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"63"}}